Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors.

After Trump threatened 25% tariffs on pharma imports, J&J became the latest pharma company to announce investments in the U.S.

Johnson & Johnson follows Eli Lilly in spending billions on U.S. manufacturing after President Donald Trump threatened major ...

Andrew Baum, Pfizer's chief strategy and innovation officer, talked Thursday about the pharmaceutical company's drug ...

Alnylam Pharmaceuticals' shares rose about 7% before the bell on Friday following U.S. approval for its drug for a rare and deadly heart disease, securing an entry into a market dominated by Pfizer's ...

Rep. Marjorie Taylor Greene calls for yanking FDA approval of COVID-19 vaccines, says that "COVID-19 vaccines are causing ...

(Reuters) -Johnson & Johnson said on Friday it plans to invest more than $55 billion over the next four years to build ...

Ovarian cancer (OC) is the fifth most common cause of cancer-related mortality worldwide and represents the leading cause of death for gynecological malignancies. Nevertheless, over the last years, ...

Gene therapy, with its offer of a possible cure for rare diseases like sickle cell, is losing early investors to ...

Despite growing competition in the transthyretin amyloid cardiomyopathy (ATTR-CM) field, Alnylam is hoping its RNA ...

The FDA approval of Alnylam’s Amvuttra sets up a three-way race with Pfizer and BridgeBio, which both market transthyretin ...